Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and ...

India's Sun Pharmaceutical Industries said on Monday it will acquire Checkpoint Therapeutics, a U.S.-based immunotherapy and ...

Indian pharma companies are expanding in the US through acquisitions to navigate regulations, diversify portfolios, and ...

A study found Indian generics sold in the US between 2009-2018 linked to a 54% higher risk of serious side effects compared ...

India’s Contract Development and Manufacturing Organization (CDMO) market is witnessing a strong growth trajectory driven by ...

Dehradun: An Indian pharmaceutical firm, whose products Singapore's Health Sciences Authority (HSA) allegedly issued images ...

The USFDA has established an office in India to oversee the number of Indian manufacturers qualified to supply generic ...

The Indian Pharmaceutical Alliance (IPA) has proposed reducing the import duty on pharma products from the US to zero.

Indian pharmaceutical CDMOs are anticipated to encounter minimal disruptions from the proposed US tariffs of 10-25 per cent.

Dilip Shanghvi, chairman of India's largest drugmaker Sun Pharma, told an industry gathering last week that his company sells ...

Indian Pharmaceutical Alliance says the study relies on FDA Adverse Event Reporting System data, which captures link between ...

Indian pharma CDMOs remain resilient, continuing to thrive due to favorable global factors. The B&K Securities report ...